FDA Warns Public Again on Risk of Sterile Drugs From Compounder

Drug Industry Daily
The FDA is warning healthcare providers and patients not to use sterile drugs made by an Oklahoma compounder after the firm refused to cease sterile operations following a failed inspection — the latest in a stream of safety alerts, warning letters and Form 483s having to do with compounders’ sterility practices over the past year.

To View This Article:


Subscribe To Drug Industry Daily